CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1065-1071

  Yasuda, Hiromi ^a   Tanaka, Koji ^a   Okita, Yoshiki ^a   Araki, Toshimitsu ^a   Saigusa, Susumu ^a   Toiyama, Yuji ^a   Yokoe, Takeshi ^a   Yoshiyama, Shigeyuki ^a   Kawamoto, Aya ^a   Inoue, Yasuhiro ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD133; NANOG; OCT4; Ulcerative colitis; Ulcerative colitis associated colorectal cancer

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG;

ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STEM CELL; ULCERATIVE COLITIS;

EID: 80052771936     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.415     Document Type: Article

References (25)

1. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535, 2001.
2. Zisman TL and Rubin DT: Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 14: 2662-2669, 2008.
3. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C and Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133: 1099-1105, 2007.
4. Watanabe T, Kobunai T, Toda E, et al: Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 13: 415-420, 2007.
5. Fujii S, Tominaga K, Kitajima K, et al: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 54: 1287-1292, 2005.
6. Nishikawa M, Oshitani N, Matsumoto T, Nishigami T, Arakawa T and Inoue M: Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer 93: 331-337, 2005.
7. Bartsch H and Nair J: Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 391: 499-510, 2006.
8. Boman BM and Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838, 2008.
9. Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP: Cancer stem cells-old concepts, new insights. Cell Death Differ 15: 947-958, 2008.
10. Shipitsin M and Polyak K: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88: 459-463, 2008.
11. Liang J, Wan M, Zhang Y, et al: Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 10: 731-739, 2008.
12. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502, 2005.
13. Wang J, Levasseur DN and Orkin SH: Requirement of Nanog dimerization for stem cell self-renewal and pluripotency. Proc Natl Acad Sci USA 105: 6326-6331, 2008.
14. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
15. Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK and Lichy JH: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47: 195-201, 2001.
16. Lanzoni G, Roda G, Belluzzi A, Roda E and Bagnara GP: Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol 14: 4616-4626, 2008.
17. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
18. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
19. Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 15: 638-648, 2008.
20. Brentnall TA, Crispin DA, Rabinovitch PS, et al: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107: 369-378, 1994.
21. Tarmin L, Yin J, Harpaz N et al: Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 55: 2035-2038, 1995.
22. Chaubert P, Benhattar J, Saraga E and Costa J: K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol 144: 767-775, 1994.
23. Farrell RJ and Peppercorn MA: Ulcerative colitis. Lancet 359: 331-340, 2002.
24. Matsumoto T, Nakamura S, Jo Y, Yao T and Iida M: Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 98: 1827-1833, 2003.
25. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB and Talbot IC: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53: 56-260, 2004.